Results 121 to 130 of about 734,643 (308)
Cardiac morphological and morphometric analysis of Ardea alba
Abstract Ardea alba (Linnaeus, 1758) is a widely distributed heron species whose cardiovascular morphology remains poorly described. This study aimed to characterize the cardiac morphology and morphometry of adult A. alba. Ten specimens were analyzed using radiographic, morphometric, histological, scanning electron microscopy, and three‐dimensional ...
Julia Vaz Feio +5 more
wiley +1 more source
Shiraz Rafiq, Jannat Atajanova, He PengyiDepartment of Cardiology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, People’s Republic of ChinaCorrespondence: He Pengyi, Department of Cardiology, The Fifth Affiliated Hospital of ...
Rafiq S, Atajanova J, Pengyi H
doaj
Background/Objectives: Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and increasingly are recognized as a continuum of interconnected conditions rather than isolated entities. Methods: A structured narrative
C\ueempeanu, Ioan-Alexandru +21 more
core +1 more source
Interventional cardiology [PDF]
M, Norell, M A, DE Belder, J, Perrins
openaire +2 more sources
Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm +2 more
wiley +1 more source
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf +15 more
wiley +1 more source
Objective Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analysed treatment‐naïve SSc‐PAH patients in EUSTAR (2000–2021) fulfilling the 2022 haemodynamic definition.
Hilde Jenssen Bjørkekjær +30 more
wiley +1 more source

